Bolero trial breast cancer

Everolimus for Advanced Breast Cancer: An Update From Breast Cancer Research, Full text, BOLERO-2 - will this Small Improvement in PFS in HER2+ Metastatic Breast

BOLERO-1: A randomized, phase III, double-blind, placebo

Daily Everolimus in Combination With Trastuzumab and The 18-month results of the phase III BOLERO-2 trial were presented at the ASCO Breast Cancer Symposium, confirming earlier survival HER2+ - Breast Cancer - HER2/ER - 2012 ASCO Annual Meeting. BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or

BOLERO-2 Trial Offers Hope to Patients With Advanced

According to the BOLERO-3 trial, adding everolimus improved survival in locally advanced or metastatic trastuzumab-resistant breast cancer. Data source: A phase III, randomized, double-blind trial among 572 patients with trastuzumab-resistant HER2-positive advanced breast cancer HER2/Neu Over-expressing Locally Advanced Breast Cancer Visit BOLERO-3 NovartisClinicalTrials. com: Pre-qualify for a trial, and view a

Afinitor/Aromasin combo disappoints in breast cancer trial Dr. Baselga Discusses the BOLERO Breast Cancer Trials Everolimus for women with trastuzumab-resistant, HER2 trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

Everolimus: Avalanche of mTOR Data in ER+ Breast Cancer The Role of Everolimus Right Now—Advanced Breast Cancer

The WIDE Program™: Clinical Trials Investigating This has launched a series of studies known as BOLERO, which stands for Breast Cancer Trials of Oral Everolimus. There are now over six of these studies Josй Baselga, MD, PhD, a professor in the Department of Medicine at Harvard Medical School and chief of